Sanofi News

IGM to Slash 73% of Workforce, Halt Two Drug Programs

Seeking Alpha13:40 ET

Vir Biotech Upgraded at Morgan Stanley on Cancer Drug Data

Seeking Alpha11:42 ET

Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report

Seeking AlphaJan 9 08:56 ET

Sanofi's Sarclisa Subcutaneous Formulation Achieves Co-Primary Endpoints In IRAKLIA Phase 3 Trial For Multiple Myeloma Treatment

BenzingaJan 9 01:28 ET

Sanofi (SNY.US) announced that the anti-CD38 monoclonal antibody has been approved in China for the treatment of multiple myeloma.

Sanofi (SNY.US) has just announced that the injection of Aishetuximab has been approved by China's National Medical Products Administration (NMPA) for market launch.

Zhitong FinanceJan 8 19:32 ET

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies

BenzingaJan 8 12:54 ET

Vir Jumps After Phase 1 Data for Sanofi-partnered Cancer Drug Technology

Seeking AlphaJan 8 08:33 ET

Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for Use of AntiClastic Antisense Platform With Sanofi

BusinesswireJan 7 10:00 ET

Sanofi Down 10% in 3 Months: How Should You Play the Stock?

Zacks Jan 7 08:35 ET

Express News | Refile-Buzz-Obesity Drugs, M&a Among Key Pharma Drivers for 2025, Berenberg Says

ReutersJan 7 08:22 ET

Berenberg Bank Sticks to Their Buy Rating for Sanofi (SNYNF)

TipRanksJan 7 04:35 ET · Ratings

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Cencora (COR)

TipRanksJan 7 02:20 ET · Ratings

Bird Flu Claims First U.S. Life in Louisiana

Seeking AlphaJan 6 17:22 ET

'LDH Reports First U.S. H5N1-Related Human Death' - Louisiana Department Of Health

BenzingaJan 6 15:35 ET

Semaglutides Market Research Report 2024-2028 & 2033 Featuring Major Players, Pfizer, Roche, Merck, AbbVie, and Sanofi

Yahoo FinanceJan 6 04:12 ET

Sanofi (SNY.US) has received approval for clinical trials of its novel dual antibody drug in China.

Recently, CDE announced that the Class 1 new drug SAR442970 injection declared by Sanofi (SNY.US) has obtained implied approval for clinical trials.

Zhitong FinanceJan 3 08:15 ET

Brand Prescription Drugs to Rise an Average 4.5% in 2025

Seeking AlphaJan 1 09:00 ET

Market Chatter: Drug Companies to Raise Prices on 250 Branded Drugs in 2025

MT NewswiresDec 31, 2024 08:38 ET

Sanofi (SNY.US) has applied for the market launch of BTK inhibitors in China.

On December 30, the CDE official website showed that Sanofi (SNY.US) has had its market application for the BTK inhibitor Rilzabrutinib accepted.

Zhitong FinanceDec 31, 2024 08:11 ET

How Is The Market Feeling About Sanofi?

BenzingaDec 30, 2024 15:15 ET